Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.